Community Acquired Bacterial Pneumonia Therapeutics
1. Nuzyra patent expiration
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of community acquired bacterial pneumonia; Treatment of subjects having...
NUZYRA's oppositions filed in EPO
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326696 | PARATEK PHARMS | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(2 years ago) | |
| US7553828 | PARATEK PHARMS | 9-aminomethyl substituted minocycline compounds |
Jun, 2025
(7 months ago) | |
| US8383610 | PARATEK PHARMS | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365500 | PARATEK PHARMS | 9-aminomethyl substituted minocycline compounds |
Jun, 2021
(4 years ago) | |
| US10383884 | PARATEK PHARMS | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9724358 | PARATEK PHARMS | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10111890 | PARATEK PHARMS | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(11 years from now) | |
| US10124014 | PARATEK PHARMS | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10835542 | PARATEK PHARMS | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9265740 | PARATEK PHARMS | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US9314475 | PARATEK PHARMS | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Dosage: TABLET; POWDER
More Information on Dosage
NUZYRA family patents
2. Tygacil patent expiration
Treatment: Method of treating bacterial infections
TYGACIL's oppositions filed in EPO
TYGACIL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40183 | PF PRISM CV | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
Apr, 2016
(9 years ago) | |
| USRE40086 | PF PRISM CV | Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines |
Jun, 2013
(12 years ago) | |
| US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(3 years from now) | |
| US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(2 months from now) | |
| US8975242 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Oct, 2028
(2 years from now) | |
| US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(4 years from now) | |
| US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(2 months from now) | |
| US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-586) | Mar 20, 2012 |
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Dosage: POWDER
More Information on Dosage
TYGACIL family patents